Search

Your search keyword '"Whitfield, Jonathan R."' showing total 41 results

Search Constraints

Start Over You searched for: Author "Whitfield, Jonathan R." Remove constraint Author: "Whitfield, Jonathan R."
41 results on '"Whitfield, Jonathan R."'

Search Results

1. MYC targeting by OMO-103 in solid tumors: a phase 1 trial

2. The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets

3. Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma

6. The effect of environmental chemicals on the tumor microenvironment

7. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead

8. Data from MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding

9. Supplementary Data from MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding

10. Abstract 3435: Identification of potential biomarkers of response to OMO-103, a first-in-modality pan-MYC inhibitor, in patients with advanced solid tumors

11. Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma

12. Supplementary Figure 3 from Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma

13. Supplementary Figure 1 from Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma

14. Supplementary Figure legends from Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma

15. Supplementary Figure 2 from Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma

16. Editorial: MYC as a disease target beyond cancer.

17. MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding

21. Abstract 1823: Translating Myc inhibition to the clinic in metastatic breast cancer

22. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy

23. Abstract B16: Targeting Myc in metastatic breast cancer by Omomyc: From proof of principle to pharmacologic approach

25. Abstract 3956: Omomyc-based cell-penetrating peptides: From proof of concept to a clinically viable anti-Myc therapy

26. BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC

27. Abstract 2167: Preclinical validation of an Omomyc cell-penetrating peptide as a viable anti-Myc therapy

30. Abstract 396: Ibrutinib exerts potent antifibrotic activity in a mouse model of pancreatic adenocarcinoma

31. Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma

32. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis

34. Abstract 1085: MYC inhibition is a potent therapy against glioma and induces mitotic crisis in cancer cells.

37. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead

38. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead

39. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis

40. The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets

41. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead

Catalog

Books, media, physical & digital resources